Medical Device Recall Trends 2024–2026: Statistics, Root Causes, and What Manufacturers Must Do

Why Recall Trends Matter Now More Than Ever

Medical device recalls reached a four-year high in 2024 with 1,059 events recorded in the United States, according to Sedgwick's 2025 US State of the Nation Recall Index. Class I recalls — the most serious category, indicating a reasonable probability of serious injury or death — hit their highest level in 15 years. Device failure surpassed process control and manufacturing defects as the leading cause of recalls for the first time in over five years.

These are not abstract statistics. Behind each recall is a patient who received a defective device, a hospital that had to pull products from shelves, and a manufacturer facing millions of dollars in remediation costs, regulatory scrutiny, and reputational damage.

This guide analyzes the data behind the recall surge, identifies the root causes, examines the regulatory response, and provides actionable strategies for manufacturers to reduce their recall risk in 2025–2026.

2024 Recall Data at a Glance

Key insight: Both recall events and units affected are rising simultaneously — events up 8.6% while units surged 55.4%. This means not only are more devices being recalled, but each recall is affecting more units on average. The combination of increasing volume and severity (Class I at a 15-year high) signals that current design and manufacturing quality controls are not keeping pace with device complexity.

Source: Sedgwick 2025 US State of the Nation Recall Index; FDA Recall Events Database; UL Solutions 2024 Recall Analysis.

Root Cause Breakdown: What's Driving Recalls

Top 10 Causes by Recall Events (2024)

Source: FDA Medical Device Recalls Database; XS Supply 2025 recall statistics compilation.

Why Device Failure Overtook Process Control

For years, process control errors — mistakes during manufacturing — dominated recall causes. In 2024, device failure (functional failures during actual use) became the leading cause. Several factors explain this shift:

1. Increased device complexity: Modern devices incorporate sensors, wireless connectivity, AI algorithms, and cloud connectivity. More functional complexity creates more failure modes that may not be caught during verification testing.

2. Software-dependent devices: Software defects now account for 8.2% of recall events and grew 31% year-over-year. As devices become more software-driven, firmware bugs, algorithm errors, and UI failures are increasingly classified as device failures rather than manufacturing defects.

3. Longer post-market observation windows: The FDA has improved its ability to mine post-market data (MAUDE database, MDR reports) to detect device performance trends, catching failures that previously went unreported.

4. QMSR transition effects: The February 2026 transition from QSR to QMSR (aligned with ISO 13485) has prompted both manufacturers and FDA to reassess risk management documentation, potentially surfacing previously overlooked device-level issues.

Software-Related Recalls: The Fastest-Growing Category

Software defects deserve special attention because they are growing faster than any other category and reflect broader industry shifts toward connected and algorithmically driven devices.

Notable Software-Driven Recalls (2024–2025)

The pattern is clear: Software is not just a secondary cause of recalls. It is increasingly the primary failure mode, affecting everything from insulin pumps to cardiology systems to compounding equipment. Manufacturers that treat software as a documentation exercise rather than a safety-critical design element are at the highest risk.

Q1 2025 Data: Is the Trend Continuing?

Preliminary data from Q1 2025 suggests the upward trend continues, though at a slightly moderated pace:

The slight decline in total events from Q4 2024 to Q1 2025 is typical of seasonal patterns. However, the annualized projection of 944 events still represents historically elevated levels, and Class I recalls continue to grow. Notably, CRC Group reports that Q1 2025's 31 Class I recalls represent the second-highest quarterly total in two decades — confirming that while total recall volume may be stabilizing, the severity of recalls continues to intensify.

Most Recalled Device Categories and Manufacturers (2024–2025)

Analysis of FDA-confirmed recalls from October 2024 through March 2025 reveals that life-support devices dominate the recall list:

Top Device Categories by Recall Count

Top Manufacturers by Recall Events

Philips' position at the top reflects ongoing scrutiny of respiratory equipment issues, suggesting systemic quality management challenges rather than isolated incidents.

Source: Drug and Device World, FDA Medical Device Recalls Database (Oct 2024–Mar 2025).

The FDA's Response: Early Alert Pilot Program

In response to rising recall activity, the FDA's Center for Devices and Radiological Health (CDRH) launched a pilot program for early alerts about potentially dangerous device failures, updates, and corrections. Key features:

• Scope: The pilot covers cardiovascular, gastrorenal, general hospital, obstetric/gynecological, and urological devices.
• Purpose: Provide earlier communication to patients and healthcare providers about potentially high-risk device issues before formal recall classification.
• Status: Event thresholds for the enhanced public alert system are still being established.

This program represents a significant shift in FDA's recall communication strategy — moving from post-classification announcements to proactive early warnings. Manufacturers should expect increased public visibility of recall events earlier in the process.

Financial Impact of Recalls

The cost of a medical device recall extends far beyond the direct expense of product retrieval:

Class I recalls trigger intensive FDA scrutiny that often extends beyond the specific product issue. Manufacturers face mandatory inspections, potential consent decrees, increased oversight, supply chain disruptions, and litigation risks. For publicly traded companies, Class I recalls frequently cause measurable stock price declines.

Risk Mitigation Strategies for Manufacturers

1. Strengthen Design Verification and Validation

With device failure as the leading recall cause, the most impactful investment is in robust design controls:

• Risk-based V&V: Prioritize verification and validation activities based on ISO 14971 risk analysis outputs. The highest-risk failure modes should receive the most rigorous testing.
• Use condition simulation: Test devices under realistic clinical conditions, not just laboratory environments. Many device failures occur in conditions that verification protocols do not adequately simulate.
• Software-specific testing: Implement penetration testing, fuzz testing, boundary value analysis, and adversarial testing for all software-dependent devices. Follow IEC 62304 testing requirements rigorously.

2. Upgrade Post-Market Surveillance

Early detection of device performance issues prevents recalls:

• Proactive complaint trending: Implement automated complaint categorization and trending analysis. Set statistical thresholds for escalation before problems become recall-grade.
• MAUDE monitoring: Regularly review FDA's MAUDE database for adverse events and MDR reports related to your devices and predicate devices.
• Real-world evidence: Collect and analyze real-world performance data through registries, post-market clinical follow-up, and electronic health record integration.

3. Address Software Lifecycle Management

Given the 31% increase in software-related recalls:

• Secure development lifecycle: Implement a Secure Product Development Framework (SPDF) as recommended by FDA cybersecurity guidance.
• SBOM management: Maintain accurate Software Bills of Materials in SPDX or CycloneDX format, and actively monitor for vulnerabilities in third-party components.
• Change control rigor: Apply the same design control discipline to software updates as to hardware changes, including risk analysis and verification.

4. Prepare for QMSR Inspection Focus Areas

With QMSR now in effect (since February 2, 2026), FDA inspections under the updated Compliance Program 7382.850 will focus on:

• Risk management documentation: How well risk analysis outputs connect to design controls, verification, and validation
• Design history files: DHF completeness and traceability from user needs through design outputs
• Process compliance: Evidence that QMS procedures are consistently followed
• Data integrity: Audit trails, electronic records compliance with 21 CFR Part 11
• Management review and internal audit records: Previously exempt from inspection, now fully accessible to FDA investigators

5. Build Recall Readiness

No manufacturer is immune to recalls. Being prepared reduces financial and regulatory impact:

• Recall SOP: Maintain a current recall procedure that covers classification, communication, effectiveness checks, and FDA reporting under 21 CFR 806.
• Traceability: Ensure lot/batch/serial traceability through distribution to enable targeted recalls rather than blanket product retrievals.
• Communication templates: Pre-draft customer notification templates, press statements, and FDA submission documents to accelerate response time.

How 2025–2026 Is Shaping Up

Several regulatory and industry developments will influence recall trends going forward:

FAQ

What is a Class I medical device recall? A Class I recall is the most serious category. It indicates a situation where there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death. Class I recalls reached a 15-year high in 2024.

Why are medical device recalls increasing? Recalls are rising due to increased device complexity (more software, connectivity, AI), improved FDA post-market surveillance capabilities, the transition to QMSR raising quality documentation expectations, and the growing number of connected devices expanding the attack surface for cybersecurity-related recalls.

What is the most common cause of medical device recalls in 2024? Device failure overtook process control as the leading cause in 2024, accounting for 11.1% of all recall events. This was the first time device failure was the top cause in over five years. Software defects grew 31% year-over-year.

How many medical device recalls occurred in 2024? There were 1,059 medical device recall events in 2024, the highest level in four years. Units affected also rose significantly to approximately 440.4 million, a 55.4% increase from 283.4 million in 2023, indicating both more frequent and larger-scope recalls.

What is the FDA early alert pilot program? The FDA launched a pilot program to provide early alerts about potentially dangerous device failures before formal recall classification. It initially covers cardiovascular, gastrorenal, general hospital, OB/GYN, and urological devices.

How can manufacturers reduce recall risk? Key strategies include strengthening design verification and validation, upgrading post-market surveillance and complaint trending, implementing secure software development lifecycles, preparing for QMSR inspections, and maintaining recall readiness with updated SOPs and traceability systems.